The long-term safety of alprostadil(prostagrandin-E1) in patients with erectile dysfunction.

The long-term safety of alprostadil(prostagrandin-E1) in patients with erectile dysfunction. - prostagrandin-E1 in patients with erectile dysfunction.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019161

Enrollment

Registered

2015-09-30

Start date

2014-08-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

erectile dysfunction

Interventions

prostagrandin-E1

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: The long-term safety of alprostadil(prostagrandin-E1) in patients with erectile dysfunction.

Exclusion criteria

Exclusion criteria: The long-term safety of alprostadil(prostagrandin-E1) in patients with erectile dysfunction.

Design outcomes

Primary

Measure	Time frame
The long-term safety of alprostadil(prostagrandin-E1) in patients with erectile dysfunction.	—

Countries

Japan

Contacts

Public ContactTakashi Imamoto

Graduate School of Medicine, Chiba University Department of Urology

t-imamo@pg7.so-net.ne.jp043-226-2134

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026